ChiCTR2500103961 版本V1.0 版本创建时间2025/06/09 15:28:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500103961 

最近更新日期:

Date of Last Refreshed on:

2025-06-09 15:28:08 

注册时间:

Date of Registration:

2025-06-09 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于国产脑灌注人工智能评价系统的慢性颅内动脉闭塞患者卒中风险评估

Public title:

Stroke risk prediction for chronic intracranial artery occlusion patients using AI-based perfusion imaging system

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于国产脑灌注人工智能评价系统的慢性颅内动脉闭塞患者卒中风险评估

Scientific title:

Stroke risk prediction for chronic intracranial artery occlusion patients using AI-based perfusion imaging system

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘德临 

研究负责人:

刘德临 

Applicant:

Delin Liu 

Study leader:

Delin Liu 

申请注册联系人电话:

Applicant telephone:

+86 138 1027 3317

研究负责人电话:

Study leader's
telephone:

+86 138 1027 3317

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dlliu2636@126.com

研究负责人电子邮件:

Study leader's E-mail:

dlliu2636@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区长椿街45号

研究负责人通讯地址:

北京市西城区长椿街45号

Applicant address:

No. 45 Chang Chun Street, Xicheng, Beijing

Study leader's address:

No. 45 Chang Chun Street, Xicheng, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2024]332号-002; 临研审[2024]332号-002-修正1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会

Name of the ethic committee:

Ethic Committee of Xuanwu Hospital Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-04 00:00:00

伦理委员会联系人:

易津

Contact Name of the ethic committee:

Jin Yi

伦理委员会联系地址:

北京市西城区长椿街45号

Contact Address of the ethic committee:

No. 45 Chang Chun Street, Xicheng, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8319 9270

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

No. 45 Chang Chun Street, Xicheng, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

北京市西城区长椿街45号

Institution
hospital:

Xuanwu Hospital Capital Medical University

Address:

No. 45 Chang Chun Street, Xicheng, Beijing

经费或物资来源:

四大慢病重大专项青年人才培育计划2023ZD0515400

Source(s) of funding:

Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0515400

研究疾病:

慢性脑动脉闭塞  

Target disease:

Chronic cerebral occlusion

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

解决无法精准预测慢性颅内动脉闭塞患者卒中风险的问题:基于智能脑灌注评估系统及已有的高质量临床队列,建立CTP预测慢性颅内动脉闭塞患者卒中风险的临床预测模型,并前瞻性验证该模型的准确性。  

Objectives of Study:

Solving the problem of unable to accurately predict stroke risk in patients with chronic intracranial artery occlusion: Based on the Intelligent Cerebral Perfusion Evaluation System and an existing high-quality clinical cohort, a clinical prediction model for predicting stroke risk in patients with chronic intracranial artery occlusion with CTP was established, and the accuracy of the model was prospectively validated.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经脑血管造影(DSA)证实为慢性颅内动脉闭塞患者; 2.出现缺血性脑卒中、TIA等相关症状; 3.接受CTP影像检查; 4.参与者及家属理解并签署知情同意书。

Inclusion criteria

1. Patients with chronic intracranial arterial occlusion confirmed by cerebral angiography (DSA); 2. Presenting with symptoms related to ischemic stroke and TIA; 3. Received CTP imaging; 4. Participants and their families understood and signed the informed consent form.

排除标准:

1.急性脑血管闭塞患者; 2.先天性闭塞或结构改变患者; 3.双侧颈内动脉或大脑中动脉闭塞患者; 4.不能接受CTP影像检查者。

Exclusion criteria:

1. Patients with acute cerebrovascular occlusion; 2. Patients with congenital occlusion or structural changes; 3. Patients with bilateral internal carotid or middle cerebral artery occlusion; 4. Patients who cannot undergo CTP imaging.

研究实施时间:

Study execute time:

From 2024-11-20 00:00:00 To 2027-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-11-24 00:00:00 To 2026-07-31 00:00:00

干预措施:

Interventions:

组别:

前瞻性队列

样本量:

231

Group:

Prospective

Sample size:

干预措施:

干预措施代码:

Intervention:

Observational

Intervention code:

组别:

回顾性队列

样本量:

330

Group:

Retrospective

Sample size:

干预措施:

干预措施代码:

Intervention:

Observational

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

聊城市人民医院 

单位级别:

三甲 

Institution
hospital:

Liaocheng People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

济南市中心医院 

单位级别:

三甲 

Institution
hospital:

Jinan Central Hospital

Level of the institution:

Tertiary A

国家:

北京

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

雄安宣武医院 

单位级别:

三甲 

Institution
hospital:

Xiong'an Xuanwu Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脑灌注

指标类型:

主要指标

Outcome:

Cerebral perfusion

Type:

Primary indicator

测量时间点:

测量方法:

CTP

Measure time point of outcome:

Measure method:

指标中文名:

卒中事件

指标类型:

主要指标

Outcome:

Stroke event

Type:

Primary indicator

测量时间点:

测量方法:

症状及MRI

Measure time point of outcome:

Measure method:

指标中文名:

预测模型准确性

指标类型:

次要指标

Outcome:

Prognostic model accuracy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果发表后公开,公开方式:联系项目负责人

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publication of result, contact project leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-09 15:28:08